Natco Pharma

Natco Pharma

Company type	Public
Traded as	NSE:  NATCOPHARM BSE:  524816
Industry	Pharmaceuticals
Founded	1981
Founder	VC Nannapaneni
Headquarters	Hyderabad, Telangana , India
Area served	Global
Key people	VC Nannapaneni (Chairman and MD) [1] Rajeev Nannapaneni (CEO and Vice Chairman) [2]
Revenue	₹4,784 crore (US$570 million) (2025)
Operating income	₹2,550 crore (US$300 million) (2025)
Net income	₹1,883 crore (US$220 million) (2025)
Website	natcopharma.co.in
Footnotes /references Financials as of 31 March 2025 [update] . [3]

Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations, active pharmaceutical ingredients and agrochemical products. ^[4] It is a major producer of branded oncology medicines ^[5] cardiology, diabetology and other pharma specialty drugs ^[6] at affordable prices. ^{[7] [8] [9] [10]}

History

• Natco Pharma was founded in 1981 by V C Nannapaneni
• In 1983, operations commenced at manufacturing facility at Nagarjunasagar, Telangana
• In 1986, the company's chemical division started at Mekaguda, Telangana
• In 2008, Natco Pharma filed its first paragraph IV filing in the US with the USFDA, ^[11]
• In 2012, Natco Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar. ^[6]
• In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences. ^[11]
• In 2016, Natco Pharma launched the first Tamiflu capsule in the US market. ^[12]
• In 2017, Natco Pharma launched a generic version of blood cancer drug Pomalidomide in the United States. ^[13]
• In 2019, Natco Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in Nellore district, Andhra Pradesh. ^[14]
• In 2022, its Crop Health Sciences division launched chlorantraniliprole (CTPR) based products.
• Natco launched the first generic version of Multiple myeloma drug Revlimid in the US market

References

1. "Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.
2. "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.
3. "Earnings Presentation - Q4 FY25 & FY25" (PDF). NATCO Pharma Limited. Retrieved 11 July 2025.
4. "Our Business | Natco Pharma" . Retrieved 25 April 2022.
5. "Natco Pharma lines up 20 'Para IV' products". The Hindu Business Line. Retrieved 19 April 2020.
6. "How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020.
7. PTI (17 December 2020). "Natco Pharma launches anti blood clot medication, Rivaroxaban, in India". The Economic Times. Retrieved 25 April 2022.
8. Akolkar, Shrikant (9 March 2017). "Natco Pharma: Top league player" (PDF). Angel One. Retrieved 25 April 2022.
9. "Mission & Heritage | Natco Pharma" . Retrieved 25 April 2022.
10. Sridhar, G. Naga (25 November 2020). "Natco Pharma expects agri business to be key growth lever". www.thehindubusinessline.com. Retrieved 24 April 2022.
11. "Niche Play". Business Today. Retrieved 19 April 2020.
12. "Bayer cancer drug faces new Nexavar patent problems in India". www.thepharmaletter.com. Retrieved 3 February 2022.
13. "Natco Pharma launches blood cancer drug priced Rs 5,000–20,000, down 98% from US price". Firstpost. 10 May 2017. Retrieved 31 July 2020.
14. "Natco Pharma to invest Rs 100 cr for setting up agrichemical facilities in Andhra". 25 January 2019.